Skip to main content

CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

Edited by:
Gabriele Picco: Translational Cancer Genomics Group, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Katia Grillone: Department of Experimental and Clinical Medicine, Oncology Laboratory, University Magna Graecia, Catanzaro, Italy
Sabrina Strano: SAFU Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Regina Elena National Cancer Institute, Rome, Italy
Alice Castelli: Istituto di Ricovero e Cura a Carattere Scientifico, Regina Elena National Cancer Institute, Rome, Italy

Submission Status: Open   |   Submission Deadline: 31st March 2024 


Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on 'CRISPR-Cas9 system, the next generation in cancer therapy and target discovery.' This special issue aims to focus on recent and innovative applications of the CRISPR-Cas9 system in cancer research and therapy.

About the collection

Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on 'CRISPR-Cas9 system, the next generation in cancer therapy and target discovery.'

The CRISPR-Cas9 system represents the latest revolution in genome editing approaches, enabling the induction of a Cas9-mediated, RNA-guided DNA double-strand break, followed by the knock-out or knock-in of a selected gene. The refinement of this technology in molecular studies has revolutionized modern biology and cancer research by allowing for the functional characterization and discovery of coding and non-coding genes that serve as biomarkers or therapeutic targets for solid and haematological malignancies. In recent years, CRISPR technology has been modified to induce increasingly precise and sophisticated genetic changes, including base editing. Additionally, the ability of CRISPR to systematically perturb genes via high-throughput screening has emerged as one of the most exciting advantages of this approach, providing powerful tools for identifying novel tumour-specific vulnerabilities, modulators of drug sensitivity and resistance mechanisms, potential regulators of tumour-immune interactions and novel immune-oncology targets. The discovery of the CRISPR-Cas9 system has expanded the applications of genetic research worldwide and is redefining the gene therapy approach, as demonstrated in recent preclinical models and clinical trials of cancer. A large amount of novel information has been gained to date, and it can be predicted that the knowledge in the field will continue to expand in the near future. This special issue aims to focus on recent and innovative applications of the CRISPR-Cas9 system in cancer research and therapy.

Keywords: CRISPR-Cas9, CRISPR-screen, genome editing, target discovery, preclinical models, precision medicine, translational oncology

  1. Chimeric antigen receptor (CAR) T-cells are a promising approach in cancer immunotherapy, particularly for treating hematologic malignancies. Yet, their effectiveness is limited when tackling solid tumors, whe...

    Authors: Liliana R. Loureiro, Lydia Hoffmann, Christin Neuber, Luise Rupp, Claudia Arndt, Alexandra Kegler, Manja Kubeil, Christoph E. Hagemeyer, Holger Stephan, Marc Schmitz, Anja Feldmann and Michael Bachmann
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:341
  2. Colorectal cancer (CRC) is one of the most common malignant cancers worldwide and seriously threatens human health. The clustered regulatory interspaced short palindromic repeat/CRISPR-associate nuclease 9 (CR...

    Authors: Yang Hu, Liang Liu, Qi Jiang, Weiping Fang, Yazhu Chen, Yuntian Hong and Xiang Zhai
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:308
  3. Immunotherapy has significantly advanced cancer treatments, but many patients do not respond to it, partly due to immunosuppressive mechanisms used by tumor cells. These cells employ immunosuppressive ligands ...

    Authors: Dong-hee Lee, Hyejin Ahn, Hye-In Sim, Eunji Choi, Seunghyun Choi, Yunju Jo, Bohwan Yun, Hyun Kyu Song, Soo Jin Oh, Kaori Denda-Nagai, Chan-Sik Park, Tatsuro Irimura, Yoon Park and Hyung-seung Jin
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:272
  4. Ewing sarcoma (ES) is an aggressive childhood bone and soft tissue cancer. KIAA1429 is one type of N6-methyladenosine (m6A) writer that plays a tumor-progressive role in various cancers, but the role of KIAA1429 ...

    Authors: Kezhe Tan, Wenjie Lu, Feng Chen, Hao Shi, Yingxuan Ma, Zhou Chen, Wei Wu, Zhibao Lv and Jialin Mo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:250
  5. The most common site of metastasis in colorectal cancer (CRC) is the liver and liver metastases occur in more than 50% of patients during diagnosis or treatment. The occurrence of metastasis depends on a serie...

    Authors: Guangshun Sun, Siqi Zhao, Zhongguo Fan, Yuliang Wang, Hanyuan Liu, Hengsong Cao, Guoqiang Sun, Tian Huang, Hongzhou Cai, Hong Pan, Dawei Rong, Yun Gao and Weiwei Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:248
  6. Glioblastoma (GBM) is the most common malignant brain tumor and has “immunologically cold” features. Changing GBM to an “immunologically hot” tumor requires a strong trigger that induces initial immune respons...

    Authors: Tsutomu Nakazawa, Takayuki Morimoto, Ryosuke Maeoka, Ryosuke Matsuda, Mitsutoshi Nakamura, Fumihiko Nishimura, Noriko Ouji, Shuichi Yamada, Ichiro Nakagawa, Young Soo Park, Toshihiro Ito, Hiroyuki Nakase and Takahiro Tsujimura
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:205
  7. The repressor element-1 silencing transcription factor (REST), a master transcriptional repressor, is essential for maintenance, self-renewal, and differentiation in neuroblastoma. An elevated expression of RE...

    Authors: Janardhan Keshav Karapurkar, Min-Seong Kim, Jencia Carminha Colaco, Bharathi Suresh, Neha Sarodaya, Dong-Ho Kim, Chang-Hwan Park, Seok-Ho Hong, Kye-Seong Kim and Suresh Ramakrishna
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:121

Submission Guidelines

Back to top

This Collection welcomes submission of Research articles and reviews. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Editorial Manager. During the submission process you will be asked whether you are submitting to a Collection, please select "CRISPR-Cas9 system, the next generation in cancer therapy and target discovery" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.